<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Transcenta Holding Limited — News on 6ix</title>
<link>https://6ix.com/company/transcenta-holding-limited</link>
<description>Latest news and press releases for Transcenta Holding Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/transcenta-holding-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68368c1178dffbe2df16cc0d.webp</url>
<title>Transcenta Holding Limited</title>
<link>https://6ix.com/company/transcenta-holding-limited</link>
</image>
<item>
<title>Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer</title>
<link>https://6ix.com/company/transcenta-holding-limited/news/transcenta-therapeutics-presents-new-data-for-its-novel-liv1-targeting-adc-tst013-demonstrating-potent-anti-tumor-activity-in-pdx-models-of-prostate-cancer-and-er-positive-her2-negative-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/transcenta-holding-limited/news/transcenta-therapeutics-presents-new-data-for-its-novel-liv1-targeting-adc-tst013-demonstrating-potent-anti-tumor-activity-in-pdx-models-of-prostate-cancer-and-er-positive-her2-negative-breast-cancer</guid>
<pubDate>Thu, 23 Apr 2026 11:00:00 GMT</pubDate>
<description>PRINCETON, N.J. and SUZHOU, China, April 23, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced the presentation of preclinical data highlighting its proprietary LIV1-targeting antibody-drug conjugates (ADC) at the 2026 AACR Annual Meeting. The data demonstrate strong anti-tumor activity, differenti</description>
</item>
<item>
<title>Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform</title>
<link>https://6ix.com/company/transcenta-holding-limited/news/transcenta-therapeutics-appoints-dr-christopher-hwang-as-head-of-global-partnerships-for-hicb-platform</link>
<guid isPermaLink="true">https://6ix.com/company/transcenta-holding-limited/news/transcenta-therapeutics-appoints-dr-christopher-hwang-as-head-of-global-partnerships-for-hicb-platform</guid>
<pubDate>Mon, 30 Mar 2026 12:30:00 GMT</pubDate>
<description>PRINCETON, N.J. and SUZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced the appointment of Dr. Christopher Hwang as Head of Global Partnerships for its Highly Intensified Continuous Bioprocessing (HiCB) platform, leading execution of the Transcenta’s global technology out-lic</description>
</item>
<item>
<title>Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/transcenta-holding-limited/news/transcenta-therapeutics-to-present-at-the-36th-annual-oppenheimer-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/transcenta-holding-limited/news/transcenta-therapeutics-to-present-at-the-36th-annual-oppenheimer-healthcare-life-sciences-conference</guid>
<pubDate>Tue, 24 Feb 2026 12:00:00 GMT</pubDate>
<description>PRINCETON, N.J. and SUZHOU, China, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics today announced that members of its senior leadership team will participate in the 36th Annual Oppenheimer Healthcare Life Sciences Conference February 25-26, 2026. 36th Annual Oppenheimer He</description>
</item>
<item>
<title>Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics</title>
<link>https://6ix.com/company/transcenta-holding-limited/news/transcenta-therapeutics-announces-strategic-collaboration-and-non-exclusive-licensing-agreement-to-advance-integrated-continuous-biomanufacturing-and-expand-global-access-to-affordable-biologics</link>
<guid isPermaLink="true">https://6ix.com/company/transcenta-holding-limited/news/transcenta-therapeutics-announces-strategic-collaboration-and-non-exclusive-licensing-agreement-to-advance-integrated-continuous-biomanufacturing-and-expand-global-access-to-affordable-biologics</guid>
<pubDate>Mon, 29 Dec 2025 00:00:00 GMT</pubDate>
<description>PRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and</description>
</item>
<item>
<title>Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia</title>
<link>https://6ix.com/company/transcenta-holding-limited/news/transcenta-therapeutics-presents-updated-efficacy-data-from-the-phase-iii-transtar102-trial-of-osemitamab-plus-nivolumab-and-capox-in-first-line-ggej-cancer-at-esmo-asia</link>
<guid isPermaLink="true">https://6ix.com/company/transcenta-holding-limited/news/transcenta-therapeutics-presents-updated-efficacy-data-from-the-phase-iii-transtar102-trial-of-osemitamab-plus-nivolumab-and-capox-in-first-line-ggej-cancer-at-esmo-asia</guid>
<pubDate>Fri, 05 Dec 2025 01:00:00 GMT</pubDate>
<description>Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 monthsPRINCETON, N.J. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, toda</description>
</item>
</channel>
</rss>